Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2

Yumei Ye, Shawn Nishi, Saraswathy Manickavasagam, Yu Lin, Ming He Huang, J. Regino Perez-Polo, Barry F. Uretsky, Yochai Birnbaum

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Several studies suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) activate peroxisome proliferator-activated receptor-γ (PPAR-γ). Atorvastatin (ATV) increases myocardial levels of prostaglandins (PG) by upregulating and activating cytosolic-phospholipase-A2 and cycloxygenase-2 (COX2). We investigated whether ATV activates PPAR-γ via 15-deoxy-delta-12,14-PGJ2 (15DPGJ2) an endogenous ligand of PPAR-γ and a product of PGD2, and to compare the effects of pioglitazone (PIO), a known direct PPAR-γ activator, to that of ATV. First we measured myocardial 15DPGJ2 levels in the rat heart after a 3-day pretreatment with oral ATV (10 mg/(kg d)), PIO (10 mg/(kg d)), ATV + PIO, ATV + COX1 inhibitor, and ATV + COX2 inhibitor. We also assessed in human umbilical venous endothelial cells (HUVEC) whether ATV and PIO activate PPAR-γ via 15DPGJ2 using siRNA targeted to PGD2 synthase. Both 15DPGJ2 levels and PPAR-γ activation were assessed. ATV and PIO increased myocardial 15DPGJ2 levels in the rat myocardium and HUVEC. siRNA inhibited this increase in both groups. Both ATV and PIO augmented PPAR-γ activation while co-treatment with siRNA completely blocked the ATV effect but only partially inhibited the PIO effect. In conclusion, both ATV and PIO activate PPAR-γ and increase myocardial 15DPGJ2 levels. Activation of PPAR-γ by ATV is mediated solely by 15DPGJ2, whereas PIO activates PPAR-γ both directly and indirectly via 15DPGJ2.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalProstaglandins and Other Lipid Mediators
Volume84
Issue number1-2
DOIs
StatePublished - Aug 2007

Fingerprint

pioglitazone
Peroxisome Proliferator-Activated Receptors
Chemical activation
Small Interfering RNA
Umbilicus
Endothelial cells
prostaglandin R2 D-isomerase
15-deoxy-delta(12,14)-prostaglandin J2
Atorvastatin Calcium
Rats
Endothelial Cells
Cytosolic Phospholipases A2
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Prostaglandin D2

Keywords

  • 15-Deoxy-delta-12,14-PGJ
  • Atorvastatin
  • Cyclooxygenase-2
  • PGD2
  • Pioglitazone
  • PPAR-gamma
  • Synthase

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2 . / Ye, Yumei; Nishi, Shawn; Manickavasagam, Saraswathy; Lin, Yu; Huang, Ming He; Perez-Polo, J. Regino; Uretsky, Barry F.; Birnbaum, Yochai.

In: Prostaglandins and Other Lipid Mediators, Vol. 84, No. 1-2, 08.2007, p. 43-53.

Research output: Contribution to journalArticle

Ye, Yumei ; Nishi, Shawn ; Manickavasagam, Saraswathy ; Lin, Yu ; Huang, Ming He ; Perez-Polo, J. Regino ; Uretsky, Barry F. ; Birnbaum, Yochai. / Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2 In: Prostaglandins and Other Lipid Mediators. 2007 ; Vol. 84, No. 1-2. pp. 43-53.
@article{81f144656a8f437daf7705c5c6adcdd0,
title = "Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2",
abstract = "Several studies suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) activate peroxisome proliferator-activated receptor-γ (PPAR-γ). Atorvastatin (ATV) increases myocardial levels of prostaglandins (PG) by upregulating and activating cytosolic-phospholipase-A2 and cycloxygenase-2 (COX2). We investigated whether ATV activates PPAR-γ via 15-deoxy-delta-12,14-PGJ2 (15DPGJ2) an endogenous ligand of PPAR-γ and a product of PGD2, and to compare the effects of pioglitazone (PIO), a known direct PPAR-γ activator, to that of ATV. First we measured myocardial 15DPGJ2 levels in the rat heart after a 3-day pretreatment with oral ATV (10 mg/(kg d)), PIO (10 mg/(kg d)), ATV + PIO, ATV + COX1 inhibitor, and ATV + COX2 inhibitor. We also assessed in human umbilical venous endothelial cells (HUVEC) whether ATV and PIO activate PPAR-γ via 15DPGJ2 using siRNA targeted to PGD2 synthase. Both 15DPGJ2 levels and PPAR-γ activation were assessed. ATV and PIO increased myocardial 15DPGJ2 levels in the rat myocardium and HUVEC. siRNA inhibited this increase in both groups. Both ATV and PIO augmented PPAR-γ activation while co-treatment with siRNA completely blocked the ATV effect but only partially inhibited the PIO effect. In conclusion, both ATV and PIO activate PPAR-γ and increase myocardial 15DPGJ2 levels. Activation of PPAR-γ by ATV is mediated solely by 15DPGJ2, whereas PIO activates PPAR-γ both directly and indirectly via 15DPGJ2.",
keywords = "15-Deoxy-delta-12,14-PGJ, Atorvastatin, Cyclooxygenase-2, PGD2, Pioglitazone, PPAR-gamma, Synthase",
author = "Yumei Ye and Shawn Nishi and Saraswathy Manickavasagam and Yu Lin and Huang, {Ming He} and Perez-Polo, {J. Regino} and Uretsky, {Barry F.} and Yochai Birnbaum",
year = "2007",
month = "8",
doi = "10.1016/j.prostaglandins.2007.04.001",
language = "English (US)",
volume = "84",
pages = "43--53",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2

AU - Ye, Yumei

AU - Nishi, Shawn

AU - Manickavasagam, Saraswathy

AU - Lin, Yu

AU - Huang, Ming He

AU - Perez-Polo, J. Regino

AU - Uretsky, Barry F.

AU - Birnbaum, Yochai

PY - 2007/8

Y1 - 2007/8

N2 - Several studies suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) activate peroxisome proliferator-activated receptor-γ (PPAR-γ). Atorvastatin (ATV) increases myocardial levels of prostaglandins (PG) by upregulating and activating cytosolic-phospholipase-A2 and cycloxygenase-2 (COX2). We investigated whether ATV activates PPAR-γ via 15-deoxy-delta-12,14-PGJ2 (15DPGJ2) an endogenous ligand of PPAR-γ and a product of PGD2, and to compare the effects of pioglitazone (PIO), a known direct PPAR-γ activator, to that of ATV. First we measured myocardial 15DPGJ2 levels in the rat heart after a 3-day pretreatment with oral ATV (10 mg/(kg d)), PIO (10 mg/(kg d)), ATV + PIO, ATV + COX1 inhibitor, and ATV + COX2 inhibitor. We also assessed in human umbilical venous endothelial cells (HUVEC) whether ATV and PIO activate PPAR-γ via 15DPGJ2 using siRNA targeted to PGD2 synthase. Both 15DPGJ2 levels and PPAR-γ activation were assessed. ATV and PIO increased myocardial 15DPGJ2 levels in the rat myocardium and HUVEC. siRNA inhibited this increase in both groups. Both ATV and PIO augmented PPAR-γ activation while co-treatment with siRNA completely blocked the ATV effect but only partially inhibited the PIO effect. In conclusion, both ATV and PIO activate PPAR-γ and increase myocardial 15DPGJ2 levels. Activation of PPAR-γ by ATV is mediated solely by 15DPGJ2, whereas PIO activates PPAR-γ both directly and indirectly via 15DPGJ2.

AB - Several studies suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) activate peroxisome proliferator-activated receptor-γ (PPAR-γ). Atorvastatin (ATV) increases myocardial levels of prostaglandins (PG) by upregulating and activating cytosolic-phospholipase-A2 and cycloxygenase-2 (COX2). We investigated whether ATV activates PPAR-γ via 15-deoxy-delta-12,14-PGJ2 (15DPGJ2) an endogenous ligand of PPAR-γ and a product of PGD2, and to compare the effects of pioglitazone (PIO), a known direct PPAR-γ activator, to that of ATV. First we measured myocardial 15DPGJ2 levels in the rat heart after a 3-day pretreatment with oral ATV (10 mg/(kg d)), PIO (10 mg/(kg d)), ATV + PIO, ATV + COX1 inhibitor, and ATV + COX2 inhibitor. We also assessed in human umbilical venous endothelial cells (HUVEC) whether ATV and PIO activate PPAR-γ via 15DPGJ2 using siRNA targeted to PGD2 synthase. Both 15DPGJ2 levels and PPAR-γ activation were assessed. ATV and PIO increased myocardial 15DPGJ2 levels in the rat myocardium and HUVEC. siRNA inhibited this increase in both groups. Both ATV and PIO augmented PPAR-γ activation while co-treatment with siRNA completely blocked the ATV effect but only partially inhibited the PIO effect. In conclusion, both ATV and PIO activate PPAR-γ and increase myocardial 15DPGJ2 levels. Activation of PPAR-γ by ATV is mediated solely by 15DPGJ2, whereas PIO activates PPAR-γ both directly and indirectly via 15DPGJ2.

KW - 15-Deoxy-delta-12,14-PGJ

KW - Atorvastatin

KW - Cyclooxygenase-2

KW - PGD2

KW - Pioglitazone

KW - PPAR-gamma

KW - Synthase

UR - http://www.scopus.com/inward/record.url?scp=34447500371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447500371&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2007.04.001

DO - 10.1016/j.prostaglandins.2007.04.001

M3 - Article

VL - 84

SP - 43

EP - 53

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 1-2

ER -